Roche’s Tecentriq (atezolizumab) Receives MHLW’s Approval as the First Immunotherapy for Extensive-Stage Small Cell Lung Cancer in Japan

 Roche’s Tecentriq (atezolizumab) Receives MHLW’s Approval as the First Immunotherapy for Extensive-Stage Small Cell Lung Cancer in Japan

Roche’s Tecentriq (atezolizumab) Receives MHLW’s Approval as the First Immunotherapy for Extensive-Stage Small Cell Lung Cancer in Japan

Shots:

  • The approval is based on P-I/III IMpower133 study assessing Tecentriq (1200mg, IV,) + CT (carboplatin and etoposide) q3w over 60mins., if tolerated subsequent infusion can be administered over 30mis. vs CT as monothx. in patients with extensive-stage small-cell lung cancer
  • The P-I/III IMpower133 study results: median OS (12.3 vs 10.3mos.); m-PFS (5.2 vs 4.3mos.); safety profile was consistent with the previous study; no new safety signals is observed
  • Tecentriq (atezolizumab) is a mAb targeting PD-L1, blocking its interaction with PD-1 and B7.1 receptor and becomes the new therapy option for patients with extensive-stage SCLC in 17yrs.

Click here to­ read full press release/ article | Ref: Chugai Pharmaceutical | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post